Suministro de Insulina y Otros para el Hrr.
La presente Base Administrativa y documentación de Licitación Pública anexada al Portal Mercado Público, tiene por objeto regular los procesos de: Licitación Pública, Apertura, Evaluación, Adjudicación, Ejecución, Recepción y Puesta en Marcha del Contrato
8 oferente(s) participaron en esta licitación. El detalle de quién compitió y con qué oferta está en el registro oficial de Mercado Público.
Ver oferentes en Mercado Público →| Código | Fecha | Proveedor | Monto |
|---|---|---|---|
| 2080-2950-SE15 | 06-04-2015 | Novo Nordisk Farmaceutica Limitada | $358.190 |
| 2080-2847-SE15 | 01-04-2015 | Aventis Pharma Holding Gmbh | $3.477.775 |
| 2080-2785-SE15 | 31-03-2015 | Novo Nordisk Farmaceutica Limitada | $195.160 |
| 2080-2737-SE15 | 30-03-2015 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-2105-SE15 | 11-03-2015 | Novo Nordisk Farmaceutica Limitada | $195.160 |
| 2080-2106-SE15 | 11-03-2015 | Novo Nordisk Farmaceutica Limitada | $3.712.800 |
| 2080-2108-SE15 | 11-03-2015 | Aventis Pharma Holding Gmbh | $4.870.075 |
| 2080-2036-SE15 | 09-03-2015 | Novo Nordisk Farmaceutica Limitada | $358.190 |
| 2080-1742-SE15 | 27-02-2015 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-1663-SE15 | 25-02-2015 | Aventis Pharma Holding Gmbh | $6.327.825 |
| 2080-1522-SE15 | 18-02-2015 | Novo Nordisk Farmaceutica Limitada | $358.190 |
| 2080-1058-SE15 | 06-02-2015 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-928-SE15 | 03-02-2015 | Novo Nordisk Farmaceutica Limitada | $341.530 |
| 2080-935-SE15 | 03-02-2015 | Aventis Pharma Holding Gmbh | $6.327.825 |
| 2080-721-SE15 | 23-01-2015 | Novo Nordisk Farmaceutica Limitada | $358.190 |
| 2080-448-SE15 | 21-01-2015 | Aventis Pharma Holding Gmbh | $6.327.825 |
| 2080-11233-SE14 | 05-01-2015 | Aventis Pharma Holding Gmbh | $5.366.900 |
| 2080-11234-SE14 | 05-01-2015 | Novo Nordisk Farmaceutica Limitada | $358.190 |
| 2080-11213-SE14 | 31-12-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-10674-SE14 | 03-12-2014 | Novo Nordisk Farmaceutica Limitada | $6.497.400 |
| 2080-10675-SE14 | 03-12-2014 | Novo Nordisk Farmaceutica Limitada | $341.530 |
| 2080-10676-SE14 | 03-12-2014 | Aventis Pharma Holding Gmbh | $4.969.440 |
| 2080-10132-SE14 | 20-11-2014 | Aventis Pharma Holding Gmbh | $3.379.600 |
| 2080-10133-SE14 | 20-11-2014 | Novo Nordisk Farmaceutica Limitada | $3.712.800 |
| 2080-9908-SE14 | 14-11-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $2.676.429 |
| 2080-9745-SE14 | 12-11-2014 | Novo Nordisk Farmaceutica Limitada | $511.700 |
| 2080-9536-SE14 | 04-11-2014 | Novo Nordisk Farmaceutica Limitada | $4.950.400 |
| 2080-9537-SE14 | 04-11-2014 | Aventis Pharma Holding Gmbh | $4.405.975 |
| 2080-9373-SE14 | 29-10-2014 | Novo Nordisk Farmaceutica Limitada | $255.850 |
| 2080-9239-SE14 | 24-10-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $1.982.421 |
| 2080-9209-SE14 | 23-10-2014 | Novo Nordisk Farmaceutica Limitada | $4.331.600 |
| 2080-9164-SE14 | 21-10-2014 | Novo Nordisk Farmaceutica Limitada | $390.320 |
| 2080-9163-SE14 | 21-10-2014 | Aventis Pharma Holding Gmbh | $3.909.150 |
| 2080-8819-SE14 | 10-10-2014 | Novo Nordisk Farmaceutica Limitada | $511.700 |
| 2080-8689-SE14 | 07-10-2014 | Aventis Pharma Holding Gmbh | $3.909.150 |
| 2080-8687-SE14 | 07-10-2014 | Novo Nordisk Farmaceutica Limitada | $4.331.600 |
| 2080-8632-SE14 | 07-10-2014 | Novo Nordisk Farmaceutica Limitada | $258.230 |
| 2080-8498-SE14 | 01-10-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $1.982.421 |
| 2080-8312-SE14 | 23-09-2014 | Novo Nordisk Farmaceutica Limitada | $4.331.600 |
| 2080-8311-SE14 | 23-09-2014 | Aventis Pharma Holding Gmbh | $3.412.325 |
| 2080-8063-SE14 | 12-09-2014 | Novo Nordisk Farmaceutica Limitada | $255.850 |
| 2080-7660-SE14 | 02-09-2014 | Novo Nordisk Farmaceutica Limitada | $4.486.300 |
| 2080-7659-SE14 | 02-09-2014 | Aventis Pharma Holding Gmbh | $5.831.000 |
| 2080-7249-SE14 | 20-08-2014 | Aventis Pharma Holding Gmbh | $2.882.775 |
| 2080-7296-SE14 | 20-08-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $1.982.421 |
| 2080-7248-SE14 | 20-08-2014 | Novo Nordisk Farmaceutica Limitada | $4.641.000 |
| 2080-6730-SE14 | 05-08-2014 | Novo Nordisk Farmaceutica Limitada | $4.641.000 |
| 2080-6731-SE14 | 05-08-2014 | Aventis Pharma Holding Gmbh | $2.915.500 |
| 2080-6522-SE14 | 28-07-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-6324-SE14 | 25-07-2014 | Aventis Pharma Holding Gmbh | $4.005.243 |
| 2080-6323-SE14 | 25-07-2014 | Novo Nordisk Farmaceutica Limitada | $4.176.900 |
| 2080-5722-SE14 | 09-07-2014 | Aventis Pharma Holding Gmbh | $4.005.243 |
| 2080-5724-SE14 | 09-07-2014 | Novo Nordisk Farmaceutica Limitada | $309.400 |
| 2080-5470-SE14 | 03-07-2014 | Novo Nordisk Farmaceutica Limitada | $3.650.920 |
| 2080-4993-SE14 | 17-06-2014 | Novo Nordisk Farmaceutica Limitada | $512.295 |
| 2080-4920-SE14 | 17-06-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
| 2080-4992-SE14 | 17-06-2014 | Aventis Pharma Holding Gmbh | $4.005.243 |
| 2080-4994-SE14 | 17-06-2014 | Novo Nordisk Farmaceutica Limitada | $3.650.920 |
| 2080-4472-SE14 | 04-06-2014 | Aventis Pharma Holding Gmbh | $4.005.243 |
| 2080-4473-SE14 | 04-06-2014 | Novo Nordisk Farmaceutica Limitada | $3.650.920 |
| 2080-4312-SE14 | 27-05-2014 | Novo Nordisk Farmaceutica Limitada | $512.295 |
| 2080-4167-SE14 | 27-05-2014 | Novo Nordisk Farmaceutica Limitada | $309.400 |
| 2080-4168-SE14 | 27-05-2014 | Aventis Pharma Holding Gmbh | $928.200 |
| 2080-4165-SE14 | 23-05-2014 | Glaxosmithkline Chile Farmaceutica Limitada | $2.035.436 |
Fuente original:ficha mercadopublico.cl
